A2A Pharmaceuticals, Inc.
10% Owner

A2A Pharmaceuticals, Inc. insider trades: Biomea Fusion (BMEA) stock buys and sales

10% Owner, Biomea Fusion Last trade Jun 1, 2023 9 Form 4 filings
$0
Sold, last 12 months
0 sales
$0
Bought, last 12 months
0 buys
9
Open-market trades
since 2021
1
Company
last trade 2023

Trades on the price chart

Daily close, with an arrow on each day they bought or sold

Companies

Where A2A Pharmaceuticals, Inc. reports to the SEC

Open-market buys and sales

9 trades reported on SEC Form 4, newest first

DateStockTypeValue
Jun 1, 2023BMEA↓ Sell$4.3M
May 12, 2023BMEA↓ Sell$846K
May 9, 2023BMEA↓ Sell$8.6M
Apr 20, 2023BMEA↓ Sell$5.8M
Mar 31, 2023BMEA↓ Sell$6.3M
Aug 16, 2022BMEA↑ Buy$426K
Jul 21, 2022BMEA↓ Sell$389K
Jun 24, 2022BMEA↓ Sell$408K
Sep 17, 2021BMEA↑ Buy$380K

Each row is one filing's trades in one stock, summed. Shares and prices are as filed, before any later stock split.

Other BMEA insiders

Open-market trades in the last 12 months

About A2A Pharmaceuticals, Inc.'s insider trades

A2A Pharmaceuticals, Inc. is a 10% owner of Biomea Fusion (BMEA). Since Sep 17, 2021, it has reported 2 open-market purchases worth $806K and 7 sales worth $26.6M on SEC Form 4. There have been no open-market trades in the last 12 months.

How to read insider trades

Officers, directors and owners of more than 10% of a company must report trades in its stock on SEC Form 4, usually within two business days. Purchases with their own money are the stronger signal: insiders sell for many reasons (taxes, diversification, a house), but buy for one. See every BMEA insider trade, the latest insider trades across the market, or cluster buys, when several insiders buy the same stock within days.